We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

2802:TSEAjinomoto Co., Inc. Analysis

Data as of 2026-08-14 - not real-time

¥5,545.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

At ¥5,545.00, Ajinomoto Co., Inc. shows no decisive moving-average alignment, leaving the trend neutral. The last 30 days have lost 10.2%. Relative strength is 57.7 — neutral — and the MACD signal is bullish. Watch ¥4,721.00 as support and ¥5,733.00 as the nearer resistance level.
The shares look overvalued at 40.2 times earnings, though no sector average was available for comparison. Analyst price targets sit 8.7% above the current price. Revenue is growing at 13.2% on a 8.5% profit margin. The 0.89% dividend yield looks covered by current payout levels.
The composite risk read is 5/10, putting it in moderate territory. With 30-day volatility of 40.5%, a beta of 0.17 and a maximum drawdown of 25.6%, position sizing matters here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.

Top Market Events

Yahoo Finance6monAJINOMOTO CO INC 2802.T Q3 FY2026 earnings call transcriptEarnings call Ajinomoto delivered record...Detailed price information for Ajinomoto CO Inc AJINF from The Globe and Mail including charting and trades.Seeking Alpha3monAjinomoto Co., Inc. AJNMY Q4 2026 Earnings Call Transcript Interpreted Good evening, everyone. Despite...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Trading above the 200-day average of 4512.35
  • MACD momentum is positive
  • 30-day price change of -10.2%

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • Trading above the 200-day average of 4512.35
  • Analyst targets imply +8.7% versus the current price
  • 30-day volatility of 40.5%

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • Analyst targets imply +8.7% versus the current price
  • Revenue growth of +13.2%
  • P/E ratio of 40.2

Key Metrics & Analysis

Financial Health

Revenue Growth13.20%
Profit Margin8.51%
P/E Ratio40.2
ROE18.49%
ROA6.72%
Debt/Equity66.23
P/B Ratio6.8
Op. Cash Flow¥227.3B
Free Cash Flow¥77.5B

Technical Analysis

TrendNeutral
RSI57.7
Support¥4,721.00
Resistance¥5,733.00
MA 20¥5,167.45
MA 50¥5,396.94
MA 200¥4,512.35
MACDBullish
VolumeIncreasing
Fear & Greed Index95.3

Valuation

Fair Value¥1,424.13
Target Price¥6,025.00
Upside/Downside8.66%
GradeOvervalued
TypeGrowth
Dividend Yield0.89%

Risk Assessment

Beta0.17
Volatility40.49%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.